ADHD Research News
New ADHD research studies referenced in this week's ADHD in the News:
- “510(k) Summary of safety and effectiveness.” U.S. Food and Drug Administration, March 24, 2014. https://www.accessdata.fda.gov/cdrh_docs/pdf13/K133382.pdf.
- Referenced in “Incorporating objective testing to add value to an ADHD diagnosis (Contemporary Pediatrics, April 25, 2024)”
- Haan, Elis, et al. “Associations between Attention-Deficit Hyperactivity Disorder Genetic Liability and ICD-10 Medical Conditions in Adults: Utilizing Electronic Health Records in a Phenome-Wide Association Study.” Psychological Medicine (April 2, 2024): 1-14. DOI: 10.1017/S0033291724000606.
- Referenced in “High genetic risk of attention deficit hyperactivity disorder suggests possible health consequences (Medical Xpress, April 19, 2024)"
- Kang, Jiseung, et al. “Prenatal Opioid Exposure and Subsequent Risk of Neuropsychiatric Disorders in Children: Nationwide Birth Cohort Study in South Korea.” BMJ 385 (April 24, 2024): e077664. DOI: 10.1136/bmj-2023-077664.
- Referenced in “Opioids during pregnancy not linked to substantially increased risk of psychiatric disorders in children (Medical Xpress, April 24, 2024)”
- Touchette, Evelyne, et al. “Longitudinal Study of Childhood Sleep Trajectories and Adolescent Mental Health Problems.” SLEEP Advances 5, no. 1 (March 7, 2024): zpae013. DOI: 10.1093/sleepadvances/zpae013.
- Referenced in “Childhood Sleep Latency Associated With Depression, ADHD in Adolescence (Psychiatry Advisor, April 23, 2024)”
Who Provides Outpatient Clinical Care for Adults With ADHD? Analysis of Healthcare Claims by Types of Providers Among Private Insurance and Medicaid Enrollees, 2021
Journal of Attention Disorders, March 18, 2024
This study from CDC researchers and CHADD PAB co-chair, Craig Surman, MD, finds that family practice physicians, psychiatrists, and nurse practitioners/psychiatric nurses were the most common providers for adults using employer-sponsored insurance, although the distribution of provider types varied across states. Lower percentages of adults with Medicaid received ADHD care from physicians. Approximately half of adults receiving outpatient ADHD care received ADHD care by telehealth.
ADHD medication and risk of cardiovascular diseases
Commentary by CHADD PAB member, Russell J. Schachar, MD, on Zhang et al. Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases, JAMA Psychiatry, November 22, 2023.
Trends in Stimulant Prescription Fills Among Commercially Insured Children and Adults—United States, 2016-2021
Morbidity and Mortality Weekly Report, March 31, 2023
Centers for Disease Control and Prevention
Summary:
What is already known about this topic?
Prescriptions for stimulants, primarily used to treat attention-deficit/ hyperactivity disorder (ADHD), were increasing for adults before the COVID-19 pandemic. Policies enacted during the pandemic expanded access to prescription stimulants via telehealth.
What is added by this report?
The percentage of adolescent and adult females and adult males receiving prescription stimulant fills increased during 2016-2021, particularly during 2020-2021.
What are the implications for public health practice?
Growing recognition of ADHD in adults and increases in prescription stimulant fills raise questions about current adult ADHD care. Development of clinical recommendations for diagnosing and managing adult ADHD could help guide safe and appropriate stimulant prescribing. Evaluation of policies enacted during the pandemic could identify benefits and harms of those policies.